In some early phase I/II clinical trials, soluble LAG-3-Ig IMP321 was used to treat advanced RCC (tumor shrinkage)37, advanced pancreatic adenocarcinoma (combined with chemotherapy but lacked activity with suboptimal dosing)38, advanced melanoma (combined with MART-1 peptide vaccination, which showed an increase in CD8+ T cell numbers and a decrease in Treg numbers)39, and metastatic breast carcinoma (phase I/II; combined with chemotherapy, which showed an objective response rate of 50%)40. The gene discussed is LAG3; the disease is neoplasm.